Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
$29.24
+6.3%
$25.28
$7.75
$31.11
$224.34M0.6145,016 shs74,608 shs
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
$3.49
-0.6%
$3.35
$1.04
$7.25
$52.21M-0.4130,448 shs11,940 shs
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$190.38
-1.1%
$182.26
$140.68
$194.48
$458.73B0.48.76 million shs6.90 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$825.86
+0.6%
$768.01
$623.78
$935.63
$781.25B0.473.51 million shs2.21 million shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
0.00%-0.71%+14.53%+57.63%+76.14%
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
0.00%+1.45%+15.18%-0.85%+181.45%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.00%-1.49%+7.13%+13.13%+14.79%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.00%+2.78%+15.69%+1.74%-8.54%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
$29.24
+6.3%
$25.28
$7.75
$31.11
$224.34M0.6145,016 shs74,608 shs
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
$3.49
-0.6%
$3.35
$1.04
$7.25
$52.21M-0.4130,448 shs11,940 shs
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$190.38
-1.1%
$182.26
$140.68
$194.48
$458.73B0.48.76 million shs6.90 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$825.86
+0.6%
$768.01
$623.78
$935.63
$781.25B0.473.51 million shs2.21 million shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
0.00%-0.71%+14.53%+57.63%+76.14%
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
0.00%+1.45%+15.18%-0.85%+181.45%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.00%-1.49%+7.13%+13.13%+14.79%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.00%+2.78%+15.69%+1.74%-8.54%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
2.57
Moderate Buy$41.2541.07% Upside
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
1.00
SellN/AN/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.77
Moderate Buy$199.054.55% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.68
Moderate Buy$938.6113.65% Upside

Current Analyst Ratings Breakdown

Latest CPIX, ASMB, LLY, and JNJ Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/24/2025
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
10/24/2025
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
10/24/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C+)
10/22/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Johnson Rice
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price TargetOutperformHold$190.00
10/22/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Loop Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$190.00
10/20/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Daiwa America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHoldStrong-Buy
10/20/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Daiwa Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeNeutralOutperform$203.00
10/20/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$840.00 ➝ $930.00
10/16/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$210.00 ➝ $215.00
10/16/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$948.00
10/15/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Argus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$210.00
(Data available from 10/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
$28.52M7.86N/AN/A$5.25 per share5.57
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
$37.87M1.38$0.26 per share13.57$1.61 per share2.17
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$88.82B5.16$13.12 per share14.51$32.90 per share5.79
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$45.04B17.35$14.24 per share57.99$15.03 per share54.95
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
-$40.18M-$5.58N/AN/AN/A-117.20%-149.01%-39.04%11/6/2025 (Estimated)
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
-$6.48M-$0.22N/AN/A-6.97%7.48%2.66%11/6/2025 (Estimated)
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$14.07B$10.3618.3817.202.2427.26%32.73%13.24%N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$10.59B$15.3053.9826.541.1925.91%92.72%16.89%10/30/2025 (Estimated)

Latest CPIX, ASMB, LLY, and JNJ Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/6/2025Q3 2025
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
-$0.50N/AN/AN/AN/AN/A
10/30/2025Q3 2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.42N/AN/AN/A$16.09 billionN/A
10/14/2025Q3 2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.76$2.80+$0.04$2.12$23.73 billion$23.99 billion
8/7/2025Q2 2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.59$6.31+$0.72$6.29$14.40 billion$15.56 billion
8/6/2025Q2 2025
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
-$1.73-$1.33+$0.40-$1.33$5.30 million$9.63 million
8/5/2025Q2 2025
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
N/A$0.02N/A-$0.05N/A$10.84 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
N/AN/AN/AN/AN/A
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
N/AN/AN/AN/AN/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$5.202.73%N/A50.19%64 Years
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.000.73%N/A39.22%11 Years

Latest CPIX, ASMB, LLY, and JNJ Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/14/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
quarterly$1.302.72%11/25/202511/25/202512/9/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
N/A
1.64
1.64
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
0.19
1.30
1.17
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.50
1.07
0.76
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.86
1.28
1.00

Institutional Ownership

CompanyInstitutional Ownership
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
19.92%
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
15.51%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
69.55%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
CompanyEmployeesShares OutstandingFree FloatOptionable
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
1007.67 million7.27 millionOptionable
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
8014.96 million8.25 millionOptionable
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
138,1002.41 billion2.41 billionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
47,000946.46 million945.23 millionOptionable

Recent News About These Companies

Pharmaceutical Stocks To Keep An Eye On - October 25th
Eli Lilly and Company $LLY Shares Bought by Curio Wealth LLC
AlTi Global Inc. Grows Holdings in Eli Lilly and Company $LLY
Eli Lilly Agrees to Acquire Adverum Biotechnologies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Assembly Biosciences stock logo

Assembly Biosciences NASDAQ:ASMB

$29.24 +1.74 (+6.33%)
Closing price 10/24/2025 04:00 PM Eastern
Extended Trading
$29.30 +0.06 (+0.21%)
As of 10/24/2025 05:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Cumberland Pharmaceuticals stock logo

Cumberland Pharmaceuticals NASDAQ:CPIX

$3.49 -0.02 (-0.57%)
Closing price 10/24/2025 03:58 PM Eastern
Extended Trading
$3.48 -0.01 (-0.14%)
As of 10/24/2025 07:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Johnson & Johnson stock logo

Johnson & Johnson NYSE:JNJ

$190.38 -2.09 (-1.08%)
Closing price 10/24/2025 03:59 PM Eastern
Extended Trading
$190.48 +0.09 (+0.05%)
As of 10/24/2025 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$825.86 +4.82 (+0.59%)
Closing price 10/24/2025 03:59 PM Eastern
Extended Trading
$826.28 +0.41 (+0.05%)
As of 10/24/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.